secukinumab

Hard-to-treat psoriasis cases respond to secukinumabSecukinumab has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis in hard-to-treat patients who failed anti-TNFa treatment, researchers report in London.
Promising new treatments for plaque psoriasisThe American College of Rheumatology annual meeting wrapped this month in San Diego. Results from long-awaited safety trials show promising new treatments.
Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Clear skin within reach for psoriasis patientsNew data presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, this week shows that secukinumab (Cosentyx, Novartis) has long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis.
Novartis announces new Cosentyx data in psoriasis treatment, including long-term studyResearchers presented new data on the use of the fully human IL-17A inhibitor Cosentyx (secukinumab, Novartis) in moderate-to-severe psoriasis, at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, September 28 through October 2, 2016.
Secukinumab approved for psoriatic arthritis and ankylosing spondylitisNovartis announced January 15 that the FDA has approved secukinumab (Cosentyx, Novartis) for psoriatic arthritis (PsA) and active ankylosing spondylitis. The announcement comes a year after the FDA’s approval for secukinumab for treatment of adults with moderate to severe psoriasis. The drug is the only IL-17A antagonist approved for all three indications. learn more
Cosentyx gets thumbs up for 2 new indicationsFDA has approved secukinumab (Cosentyx, Novartis) for the treatment of adult patients with active ankylosing spondylitis and active psoriatic arthritis.
FDA approves secukinumab for psoriatic arthritisNovartis announced January 15 that the FDA approved Cosentyx (secukinumab) for psoriatic arthritis and active ankylosing spondylitis.
Can you maintain response after biologic holiday?Melinda Gooderham, M.D., MSc, FRCPC Patients might stop taking their biologic medications for a variety of reasons. When patients do stop their biologic therapy, clinicians need to consider that some biologic therapies are better at recapturing response than others. learn more
New psoriasis therapies must demonstrate valuePsoriasis affects a small percentage of the population but price increases for drug treatments have outpaced the Consumer Price Index.